CPT Code 11900: Injection, Intralesional; Up to 7 Lesions

Key Takeaways

CPT 11900 covers intralesional injections for up to 7 lesions

Use 11901 when treating more than 7 lesions in one session

Bill medications separately using appropriate HCPCS J-codes

Count lesions, not individual needle insertions or injection sites

Documentation must specify lesion location, count, and medication used

Introduction to CPT Code 11900

CPT code 11900 is the billing code for intralesional injections of up to and including seven lesions. Dermatology and podiatry practices use this code daily for procedures ranging from corticosteroid injections for keloid scars to triamcinolone treatment for alopecia areata. The distinction between 11900 and its companion code 11901 hinges on lesion count, not the number of injections administered.

According to the American Medical Association’s CPT code set overview, intralesional injections involve delivering medication directly into a skin lesion rather than into surrounding tissue. This targeted approach treats conditions where systemic medication would be less effective or require higher doses with increased side effect risks. Practices frequently pair CPT 11900 with HCPCS code J3301 for Kenalog (triamcinolone acetonide), though medication billing requires separate coding.

What is CPT Code 11900?

CPT 11900 describes the injection of a non-chemotherapeutic substance into one to seven lesions. The procedure involves inserting a needle directly into the lesion and depositing medication within its boundaries. Common clinical applications include treating hypertrophic scars, keloids, cystic acne nodules, psoriatic plaques, warts resistant to topical treatment, and inflammatory skin conditions localised to specific areas.

The code applies regardless of how many times you puncture each lesion. If you inject one lesion three times to distribute medication evenly, you still count it as one lesion. The Centers for Medicare & Medicaid Services (CMS) HCPCS overview clarifies that lesion count determines code selection, not injection frequency or needle insertions per lesion.

CPT Code 11900: Definition and Scope

The official CPT descriptor reads: “Injection, intralesional; up to and including 7 lesions.” This wording establishes an inclusive upper boundary. Treating exactly seven lesions falls under 11900. Treating the eighth lesion requires switching to CPT 11901, which covers eight or more lesions as a standalone code, not an add-on.

Intralesional injections differ from subcutaneous injections (CPT 96372) in that the medication goes into the lesion itself. The distinction matters for both clinical efficacy and billing accuracy. Claims management software configured for dermatology practices typically includes edits flagging common confusion between these codes.

Clinical Indications for CPT 11900

Dermatologists most commonly use CPT 11900 for corticosteroid injections treating keloid scarring and hypertrophic scar tissue. Triamcinolone concentrations typically range from 10mg/mL to 40mg/mL depending on lesion thickness and location. Alopecia areata patches respond to intralesional steroid injection, particularly when limited to seven or fewer distinct areas of hair loss.

Podiatry practices apply 11900 for plantar wart treatment using various injectable agents. Cystic acne treatment with intralesional triamcinolone represents another frequent application, particularly for inflamed nodules requiring rapid resolution before scarring occurs. Psoriatic plaques resistant to topical therapy may receive intralesional methotrexate or corticosteroids, though severe cases might require systemic treatment instead.

CPT Code 11900 vs CPT Code 11901

The numerical threshold between CPT 11900 and 11901 creates a bright-line rule. Seven lesions or fewer: use 11900. Eight or more: use 11901. These codes never appear on the same claim for the same date of service. They represent mutually exclusive choices, not a base code plus add-on structure.

This distinction trips up billers accustomed to add-on codes in other CPT sections. Unlike surgical procedures where you might bill a primary code plus additional codes for extra work, 11901 stands alone. According to Coding Intel’s dermatologic procedures guidance, reporting both codes together for the same session violates CPT conventions and triggers claim denials.

When to Use CPT Code 11900 Instead of 11901

Count every distinct lesion receiving medication. A patient presenting with five keloid scars on the chest and two on the shoulder: that’s seven lesions, coded as 11900. The same patient returning next month with three new keloids brings the session total to three lesions, again coded as 11900.

The count resets with each date of service. Yesterday’s seven-lesion treatment doesn’t combine with today’s two-lesion treatment to reach nine. Each session stands alone. Appointment scheduling systems integrated with billing platforms can flag when a patient nears the seven-lesion threshold, prompting documentation review before the session ends.

Lesion Counting Rules for Billing

Multiple injections into one lesion still count as one lesion. A 2cm keloid might require three needle insertions to distribute triamcinolone throughout the scar tissue. That’s one lesion injected three times, not three lesions. The physical boundary of the lesion defines the count, not your injection technique.

Contiguous lesions present a grey area. If psoriatic plaques merge into a continuous affected area, some payers consider it one lesion. Others expect you to count distinct disease sites even if they adjoin. ResDAC’s coding resources recommend checking your Medicare Administrative Contractor’s local coverage determination for region-specific guidance.

Automate CPT Code 11900 Documentation

Pabau's dermatology-focused practice management system streamlines intralesional injection documentation, automatic lesion counting, and integrated billing workflows.

Book a demo

Documentation Requirements for CPT Code 11900

Medicare Administrative Contractors and commercial payers require specific documentation elements to support CPT 11900 claims. The medical record must include the exact number of lesions treated, anatomical location of each lesion, medication name and concentration, and volume injected per lesion. Missing any of these elements invites claim denials or documentation requests.

Template-based documentation systems reduce omission errors. A structured note prompting clinicians to record lesion location, count, medication specifics, and response to previous treatments creates audit-resistant records. Digital clinical forms configured with mandatory fields prevent incomplete documentation from reaching the billing queue.

Essential Documentation Elements

Anatomical specificity matters. “Left arm” lacks sufficient detail. “Left posterior upper arm, 4cm superior to olecranon” meets documentation standards. When treating multiple lesions in one anatomical region, distinguish them with measurements, landmarks, or body diagrams. Three keloids on the chest need distinct identifiers: “anterior chest wall, 2cm left of midline at fourth intercostal space” provides clearer documentation than “chest, left side.”

Medication documentation extends beyond the drug name. Record the concentration (10mg/mL triamcinolone vs 40mg/mL), total volume per lesion, and manufacturer if billing requires National Drug Codes. For compounded preparations, note the compounding pharmacy and lot number. This level of detail supports both medical necessity and medication billing through separate HCPCS codes.

Medical Necessity and Diagnosis Codes

ICD-10-CM diagnosis codes must justify the intralesional injection. L91.0 (hypertrophic scar) supports keloid treatment. L63.9 (alopecia areata, unspecified) covers hair loss injections. L70.0 (acne vulgaris) applies to cystic acne nodule injections. The diagnosis code must match the treated condition and support the intervention’s appropriateness.

Prior treatment documentation strengthens medical necessity arguments. Notes indicating failed topical therapy or progressive lesion growth demonstrate that intralesional injection represents appropriate escalation rather than first-line treatment. Payer policies increasingly require evidence of conservative management attempts before approving more invasive interventions. Dermatology EMR software can track treatment progression automatically, building medical necessity arguments through longitudinal documentation.

Billing CPT Code 11900 with Medication Codes

CPT 11900 covers the injection procedure only. The medication requires separate billing through HCPCS J-codes. This separation frequently confuses practices new to intralesional injection coding. You submit two lines on the claim: one for the injection service (11900) and one for the drug administered (typically J3301 for triamcinolone).

J3301 bills per 10mg of triamcinolone. Injecting 40mg of triamcinolone into seven lesions requires calculating total drug volume. If each lesion receives 0.5mL of 40mg/mL triamcinolone, that’s 20mg per lesion, 140mg total. Divide 140mg by 10mg to get 14 units of J3301. According to CMS Physician Fee Schedule lookup, medication units must accurately reflect administered quantities to avoid overpayment recoupment.

Common Medication Codes Paired with CPT 11900

J3301 (triamcinolone acetonide, per 10mg) represents the most common pairing with 11900. Kenalog formulations come in multiple concentrations: 10mg/mL, 40mg/mL, and 80mg/mL. Your documentation must specify the concentration to calculate units correctly. Some practices use triamcinolone hexacetonide (J3300) for longer-acting effects, though it bills per 5mg instead of 10mg.

Other injectables require different J-codes. Intralesional interferon for warts uses J9214. Intralesional fluorouracil for certain dermatologic conditions codes to J9190, though chemotherapeutic intralesional injections actually use CPT 96405 instead of 11900. This distinction matters: 11900 explicitly excludes chemotherapeutic agents from its descriptor.

Calculating Drug Units for Billing

Concentration × Volume = Total mg. That total mg ÷ J-code increment = Billable units. Example: You inject 0.3mL of 10mg/mL triamcinolone into six lesions. That’s 3mg per lesion, 18mg total. 18mg ÷ 10mg per unit = 1.8 units. Round to 2 units for billing. Never round down medications; always round up to the next whole unit.

Wastage documentation becomes critical when vial contents exceed administered amounts. A 1mL vial of 40mg/mL triamcinolone contains 40mg total. If you only use 0.2mL (8mg) for a patient’s two lesions, you bill 1 unit of J3301 but discard 32mg. Some payers require discarded quantity documentation. Others accept standard wastage as practice cost. Check your payer policies before assuming wastage coverage.

Reimbursement and Payment for CPT Code 11900

Medicare reimbursement for CPT 11900 varies by geographic region due to practice expense and malpractice cost differences. The 2026 national average non-facility payment sits around $68, though actual rates range from $55 in lower-cost areas to $82 in high-cost urban regions. These figures represent the complete payment including patient responsibility.

Commercial payers typically reimburse 110% to 150% of Medicare rates for CPT 11900, depending on contract negotiations and network status. Out-of-network rates can reach 200% to 300% of Medicare levels. Revenue cycle management tools help practices track payer-specific reimbursement patterns and identify underpayments requiring appeal.

Medicare Payment Rates

The Medicare Physician Fee Schedule updates annually, typically releasing in November for the following year. Geographic Practice Cost Indices (GPCI) adjust base rates for different locations. Manhattan providers receive higher reimbursement than rural Alabama clinics for identical services due to practice expense differences. Work RVU remains constant at 1.45 for 11900 across all locations.

Place of service affects payment rates. The non-facility rate applies when you perform the injection in your office or clinic. The facility rate (typically 30% to 40% lower) applies when you inject in a hospital outpatient department or ambulatory surgical centre. Most intralesional injections occur in office settings, qualifying for the higher non-facility rate.

Commercial Payer Policies

Blue Cross Blue Shield plans generally cover CPT 11900 without prior authorization for accepted indications like keloid treatment and cystic acne. Some plans limit the number of lesions per year or require photographic documentation for continued treatment beyond three sessions. Policy variations between Blue Cross entities in different states mean Texas Blue Cross might cover what California Blue Cross denies.

UnitedHealthcare typically requires medical records demonstrating failed conservative therapy before approving multiple intralesional injection sessions. Aetna may bundle intralesional injections with office visits when performed on the same date, reducing separate payment. Understanding payer-specific policies before performing procedures prevents surprise denials. Blue Cross NC’s CPT/HCPCS search tool provides one state’s policy example, though national commercial payers maintain separate guidelines.

Common Billing Errors with CPT Code 11900

The most frequent error involves miscounting lesions. Billers count needle sticks instead of lesions, inflating the total and triggering code selection errors. A patient with three keloids receiving two injections each generates claims for 11901 (because 6 > 7) when 11900 was appropriate. This error reverses too: treating eight distinct lesions but billing 11900 because you only used one syringe.

Modifier misuse creates another common problem. Some practices append modifier 51 (multiple procedures) to 11900 when billing multiple services the same day. CPT 11900 already accounts for multiple lesions up to seven; adding modifier 51 suggests separate distinct procedures rather than the inclusive service 11900 describes. The CMS list of CPT/HCPCS codes clarifies which codes permit modifier 51.

Lesion Count Documentation Failures

Vague documentation like “multiple lesions treated” fails to justify either 11900 or 11901. Auditors need exact counts. “Four lesions on trunk” meets the standard. “Several lesions, trunk area” invites denial. Body diagrams with numbered lesion markers provide clear documentation that photographs alone might not convey, since images show lesion appearance but not always boundaries distinguishing one lesion from adjacent ones.

Inconsistent counts between different sections of the medical record trigger scrutiny. The procedure note says “seven lesions treated” but the assessment mentions “multiple sites” and the billing sheet shows 11900 with J3301 units suggesting 10 lesions worth of medication. These discrepancies suggest either documentation errors or billing fraud, neither of which you want auditors investigating.

Medication Billing Errors

Forgetting to bill the drug separately leaves significant revenue unclaimed. The medication often represents 40% to 60% of the total claim value. Practices accustomed to bundled payment models sometimes assume 11900 includes the drug cost, but it doesn’t. You must submit both the procedure code and appropriate J-codes to receive full payment.

Incorrect unit calculations on J-codes trigger recoupment demands. Billing 10 units of J3301 when you actually administered 3 units worth of triamcinolone creates an overpayment that audits will identify. Skin clinic management software with integrated medication tracking prevents quantity errors by calculating J-code units automatically from documented medication administration records.

Modifiers and Special Circumstances for CPT 11900

Modifier 59 (Distinct Procedural Service) applies when you perform intralesional injections and another procedure with a National Correct Coding Initiative edit against them on the same date. For example, if you excise a lesion and inject separate lesions during the same encounter, modifier 59 on the excision code clarifies they’re distinct services not components of one procedure.

Modifier 76 (Repeat Procedure by Same Physician) comes into play when unusual circumstances require repeating intralesional injections the same day. A patient returns the same afternoon because initial lesion injection extravasated requires re-injection. Without modifier 76, the second claim looks like a duplicate and gets denied. Documentation must explain why the repeat procedure was medically necessary.

Bilateral and Multiple Site Modifiers

CPT 11900 doesn’t use bilateral modifiers (50, LT, RT) because it counts total lesions regardless of body side. Treating three lesions on the right arm and four on the left arm: that’s seven total lesions, one unit of 11900. The code descriptor’s “up to and including 7 lesions” encompasses anatomical distribution without requiring side-specific reporting.

Anatomic modifiers for separate body areas don’t apply either. Unlike some surgical codes where you append modifiers for different anatomical regions, 11900 aggregates all treated lesions into one reportable service. This simplifies billing but requires meticulous lesion count documentation to prevent disputes about whether you actually treated seven versus eight lesions.

Global Period Considerations

CPT 11900 carries a 0-day global period, meaning no postoperative care is bundled into the procedure payment. Same-day evaluation and management services require modifier 25 when medically necessary and separately identifiable from the injection decision. If you examine the patient, document new findings, and then decide to inject lesions, both the E/M and 11900 bill separately.

Follow-up visits after intralesional injection bill as new encounters. Unlike surgical procedures with 10-day or 90-day global periods including postoperative checks, CPT 11900 doesn’t bundle future visits. When a patient returns two weeks later for lesion evaluation, that visit bills at full rate with its own E/M code. This billing structure better reflects dermatology practice patterns where injection response assessment represents substantive clinical work.

Related CPT Codes and Alternatives

CPT 96372 (therapeutic, prophylactic, or diagnostic injection, subcutaneous or intramuscular) appears similar but covers different injection routes. Subcutaneous and intramuscular injections deliver medication beneath the skin or into muscle tissue, not into a lesion itself. Administering a systemic corticosteroid injection for allergic reaction uses 96372. Injecting that corticosteroid into a keloid uses 11900.

CPT 96405 (chemotherapy administration, intralesional, up to and including 7 lesions) parallels 11900’s structure but applies exclusively to chemotherapeutic agents. Intralesional fluorouracil for actinic keratoses codes to 96405, not 11900. The medication type determines code selection: non-chemo gets 11900, chemo gets 96405. Prescription management systems can flag medication classes to guide correct procedure code selection during documentation.

CPT Code 11901: More Than 7 Lesions

As discussed, CPT 11901 covers intralesional injections of eight or more lesions. The code stands alone, not as an add-on to 11900. Some practices mistakenly bill 11900 plus additional units when treating more than seven lesions. This violates CPT guidelines. One date of service, one code: either 11900 for up to seven lesions or 11901 for eight or more.

The reimbursement difference between 11900 and 11901 reflects increased work for additional lesions but doesn’t scale linearly. Medicare pays approximately 25% to 30% more for 11901 than 11900, even though treating 15 lesions requires more than twice the work of treating seven. This compression means high-volume intralesional injection sessions generate proportionally less revenue per lesion as count increases.

Trigger Point Injections vs Intralesional Injections

CPT 20552 and 20553 cover trigger point injections into muscle, not skin lesions. Confusion arises when practitioners inject painful scars, since the injection site involves scar tissue possibly overlying muscle. The determining factor: therapeutic target. Injecting the scar tissue itself for scar modification uses 11900. Injecting underlying muscle for pain relief uses 20552/20553.

Documentation distinguishes these procedures. “Intralesional triamcinolone to hypertrophic scar” clearly indicates 11900. “Trigger point injection, trapezius muscle, near scar site” points to 20552. When both occur during one encounter, both codes bill with appropriate modifiers indicating distinct services at separate anatomical targets.

Expert Picks

Expanding your dermatology procedure offerings? Best Aesthetic Clinic Software reviews platforms supporting complex billing scenarios and multi-specialty coding.

Managing high-volume injection sessions? Client Record Management streamlines documentation workflows for repetitive procedures like intralesional injections.

Need to verify medication administration records? Inventory Management Software tracks medication usage to support J-code billing accuracy and prevent wastage documentation issues.

Conclusion

CPT code 11900 serves as the foundation for intralesional injection billing in dermatology and podiatry practices. Mastering the distinction between 11900 and 11901 based on lesion count, billing medications separately through HCPCS J-codes, and maintaining documentation that specifies lesion location, count, and treatment details prevents the majority of claim denials. The procedure’s 0-day global period simplifies follow-up billing while the lack of bilateral or anatomic modifiers reduces administrative complexity.

Practices that implement structured documentation templates, calculate medication units accurately, and understand payer-specific policies maximize both clinical outcomes and revenue capture. As intralesional injection techniques expand to new indications and medications, staying current with CPT updates and payer coverage determinations remains essential for compliant billing and optimal reimbursement.

Frequently Asked Questions